Nicolás Tambucho, CEO of Guska, took part in the LSX World Congress in Lisbon as part of Spring Innovation Week.
“It was a highly enriching experience, where we connected with the biotech ecosystem, learned from industry leaders, and held meetings that bring us closer to advancing our developments,” he noted.
Tambucho also presented Guska’s latest progress during the Biotech Startup Showcase.
The LSX World Congress in Lisbon brings together leaders from life sciences startups with high-impact investors and collaborators.
“At Guska, we are building RNA-based oncolytic virotherapies aimed at tackling some of the most aggressive solid tumors, including glioblastoma and pancreatic cancer, through a dual mechanism: direct tumor cell lysis and activation (training) of the immune system to recognize tumor-specific neoantigens. I’m convinced that with a purpose like the one we have at Guska, we will find a way forward to help patients who today have limited treatment options,” Tambucho added.
